Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (121-130 of 188) with videos related to

Pageof 19
Sort By:
American Journal of Medical Genetics. Part A|May 7, 2019
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinomaChiara Leoni, Giuseppe Gullo, Nicoletta Resta, et al.
Cancers|April 20, 2019
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer CellsPatricia Gaule, Nupur Mukherjee, Brendan Corkery, et al.
Carcinogenesis|June 7, 2013
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysisColin Clarke, Stephen F Madden, Padraig Doolan, et al.
Dalton Transactions (Cambridge, England : 2003)|August 4, 2010
Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agentsAine Mooney, Alan J Corry, Cliodhna Ní Ruairc, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Anticancer Research|August 15, 2002
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot studyAntonio Fabiano Ferreira Filho, John Crown, Fatima Cardoso, et al.
Irish Journal of Medical Science|July 14, 2023
Pilot study of the implementation of G8 screening tool, Cognitive screening assessment and Chemotherapy Toxicity assessment in older adults with cancer in a Tertiary University Hospital in IrelandMaha AlSendi, Calvin R Flynn, Muhammad R Khan, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass IndexChristine Desmedt, Marco Fornili, Florian Clatot, et al.
Molecular Biosystems|December 9, 2014
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancerPaul Dowling, Damian Pollard, AnneMarie Larkin, et al.
Pageof 19

Showing results (121-130 of 188) with videos related to

Sort By:
Pageof 19
American Journal of Medical Genetics. Part A|May 7, 2019
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinomaChiara Leoni, Giuseppe Gullo, Nicoletta Resta, et al.
Cancers|April 20, 2019
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer CellsPatricia Gaule, Nupur Mukherjee, Brendan Corkery, et al.
Carcinogenesis|June 7, 2013
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysisColin Clarke, Stephen F Madden, Padraig Doolan, et al.
Dalton Transactions (Cambridge, England : 2003)|August 4, 2010
Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agentsAine Mooney, Alan J Corry, Cliodhna Ní Ruairc, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Anticancer Research|August 15, 2002
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot studyAntonio Fabiano Ferreira Filho, John Crown, Fatima Cardoso, et al.
Irish Journal of Medical Science|July 14, 2023
Pilot study of the implementation of G8 screening tool, Cognitive screening assessment and Chemotherapy Toxicity assessment in older adults with cancer in a Tertiary University Hospital in IrelandMaha AlSendi, Calvin R Flynn, Muhammad R Khan, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass IndexChristine Desmedt, Marco Fornili, Florian Clatot, et al.
Molecular Biosystems|December 9, 2014
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancerPaul Dowling, Damian Pollard, AnneMarie Larkin, et al.
Pageof 19